An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

Colitis, Ulcerative Clinical Trial

Official title:

A Phase 2, Open-Label, Multicenter Study to Explore the Efficacy and Safety of MONGERSON (GED-0301) in Subjects With Active Ulcerative Colitis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02601300
• Other study ID #: GED-0301-UC-002
• Status: Completed
• Phase: Phase 2
• Start date: December 14, 2015
• Est. completion date: August 8, 2017

Study information

• Verified date: October 2018
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2, open-label, multicenter study to explore the efficacy and safety of oral GED- 0301 in subjects with active UC, defined as a modified Mayo score (MMS) ≥ 4 and ≤ 9 and a Mayo endoscopic subscore≥ 2.

Approximately 40 subjects will be enrolled using an Interactive Voice Response System (IVRS) or an Interactive Web Response System (IWRS) to receive open-label, oral GED-0301 160 mg for duration of 52 week treatment. Enrollment of subjects with previous exposure to TNF-α blockers will be limited to approximately 15 subjects. The number of subjects with extensive colitis is targeted to comprise approximately 50% of the entire study population.

Description:

Eligible subjects will have the Baseline Visit (Week 0/ Visit 2) and receive the following treatments:

• Induction Phase - GED-0301 160 mg once daily (QD) for 8 weeks;

• Extension Phase - GED-0301 160 mg on alternating dosing schedule (GED-0301 160 mg QD for 4 weeks, followed by 4 weeks without GED-0301 treatment) for an additional 44 weeks. Subjects who do not achieve at least a 20% decrease in partial mayo score (PMS) from baseline at Week 12 will be discontinued from the study.

Clinical, safety, and pharmacokinetic (PK) data will be evaluated on an ongoing basis, however, if the response to treatment is lower than expected (eg, ≤2 subjects achieving clinical remission based on modified Mayo score (MMS)) when 50% of the subjects complete Week 8, or discontinue before Week 8, the study team will review available data (clinical, safety, and PK) to evaluate if the study conduct should be modified.

This evaluation will be based on clinical judgment and the following guidance

• Consider starting a new cohort of subjects using a QD dose up to 320 mg if there is endoscopic or histologic evidence of proximal colon benefit but limited or no distal colon drug exposure/efficacy. Also, there is evidence of potential overall efficacy (total Mayo score (TMS), MMS,PMS) outcomes and acceptable safety (adverse events (AEs)/vitals/clinical laboratory test results) and exposure (PK).

• Consider to terminate the study if there is no evidence of drug exposure/efficacy in the colon observed by endoscopy or biopsy nor evidence of potential overall efficacy (TMS, MMS, PMS) outcomes or unacceptable safety(AEs/labs/vitals) or exposure (PK).

• Continue the study with the GED-0301 160 mg QD dose. If the GED-0301 160 mg QD dose group is discontinued and a new dose group is added, an additional 40 subjects will be enrolled in the new dose group. Subjects enrolled subsequent to the decision to adjust the dose of GED-0301, will receive the following treatments:

• Induction Phase - GED-0301, up to 320 mg QD, for 8 weeks;

• Extension Phase- GED-0301, up to 320 mg on alternating dosing schedule (GED-0301, up to 320 mg QD for 4 weeks, followed by 4 weeks without GED-0301 treatment) for an additional 44 weeks. Subjects who do not achieve at least a 20% decrease in the PMS from baseline at Week 12 will be discontinued from the study. Actively enrolled subjects will not be affected by the dose adjustment. Subjects receiving corticosteroids at baseline will start tapering their corticosteroids at Week 8 (the end of the Induction Phase) if they achieve clinical response, defined as a decrease from baseline of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS ≤ 1 in the MMS. The endoscopy subscore assessed by the investigator will be used for the calculation of the Week 8 MMS.

The study will consist of 4 phases:

• Screening Phase - up to 4 weeks

• Induction Phase - 8 weeks

• Extension Phase - 44 weeks

• Observational Follow-up Phase - 4 weeks Subjects who complete the Extension Phase, and those subjects who prematurely discontinue from the study for any reason, will enter the post-treatment Observational Follow-up Phase, the 4-week period after the last dose of Investigational Product(IP). The study will be conducted in compliance with International Conference on Harmonisation (ICH) Good Clinical Practices (GCPs).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: August 8, 2017
• Est. primary completion date: September 6, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Inclusion Criteria:

• Subjects must satisfy the following criteria to be enrolled in the study:

1. Subject is = 18 years of age at the time of signing the informed consent form (ICF).

2. Subject is able to understand and voluntarily sign an informed consent form (ICF)prior to conducting any study related assessments/procedures.

3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.

4. Subject must have diagnosis of Ulcerative Colitis (UC) with a duration of at least 3 months prior to screening.

5. Subject must have moderate to severe Ulcerative Colitis (UC), defined as Modified Mayo score (MMS) = 4 to = 9 with rectal bleeding subscore (RBS) = 1 at screening.

6. Subject must have a Mayo endoscopic subscore = 2 at screening.

7. Subject must have failed or experienced intolerance to at least one of the following:

aminosalicylates; budesonide; systemic corticosteroids; immunosuppressants (eg,6-mercaptopurine (6-MP), or azathioprine (AZA)) or Tumor necrosis factor (TNF)-a blockers (eg, infliximab, adalimumab, or golimumab)

8. Subject must meet the following laboratory criteria:

1. White blood cell count = 3000/mm3 (= 3.0 X 109/L)

2. Platelet count = 100,000/mm3 (= 100 X 109/L)

3. Serum creatinine = 1.5 mg/dL (= 132.6 µmol/L)

4. Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase (SGOT)) and alanine transaminase (ALT/serum pyruvic transaminase (SGPT)2.5 X upper limit of normal (ULN)

5. Total bilirubin = 2 mg/dL (= 34 µmol/L) unless there is a confirmed diagnosis of Gilbert's disease

6. Hemoglobin = 9 g/dL (= 5.6 mmol/L)

7. Activated partial thromboplastin time (APTT) 1.5 X ULN

9. Females of childbearing potential (FCBP) must have a negative pregnancy test at the Screening and Baseline Visits. While on Investigational Product (IP)and for at least 28 days after taking the last dose of Investigational Product (IP), females of childbearing potential (FCBP) who engage in activity in which conception is possible must use one of the approved contraceptive options described below: Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom PLUS 1 additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

10. Male subjects (including those who have had a vasectomy) when engaging in sexual activity with females who are able to become pregnant must use barrier contraception (male latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) while on Investigational Product (IP) and for at least 28 days after the last dose.

Exclusion Criteria:

• The presence of any of the following will exclude a subject from enrollment:

1. Subject has a diagnosis of Crohn's Disease (CD), indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis.

2. Subject has ulcerative colitis restricted to distal 15 cm or less (eg, ulcerative proctitis).

3. Subject had surgery as a treatment for ulcerative colitis (UC)or who, in the opinion of the Investigator, is likely to require surgery for ulcerative colitis (UC) during the study.

4. Subject has clinical signs suggestive of fulminant colitis or toxic megacolon.

5. Subject is stool positive for any enteric pathogen or Clostridium difficile (C. difficile) toxin at screening.

6. Subject has history of colorectal cancer or colorectal dysplasia.

7. Prior treatment with more than 2 Tumor necrosis factor (TNF)-a blockers (eg, infliximab, adalimumab, or golimumab).

8. Prior treatment with any integrin antagonists (eg, natalizumab or vedolizumab).

9. Use of Tumor necrosis factor (TNF)-a blockers within 8 weeks of the screening.

10. Subject had prior treatment with mycophenolic acid, tacrolimus, sirolimus, cyclosporine, thalidomide or apheresis (eg, Adacolumn®) for the treatment of ulcerative colitis (UC). In addition, prior use of any of these treatment modalities for an indication other than ulcerative colitis (UC) within 8 weeks of screening is also excluded.

11. Subject has received intravenous (IV) corticosteroids within 2 weeks of screening.

12. Subject has received topical treatment with 5 aminosalicylic acid (5-ASA) or corticosteroid enemas or suppositories within 2 weeks of screening.

13. Subject has received total parenteral nutrition (TPN) within 4 weeks of screening.

14. Subject has a history of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the investigator's opinion, would prevent the subject from participation in the study.

15. Subject has any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she was to participate in the study or confounds the ability to interpret data from the study.

16. Subject is pregnant or breastfeeding.

17. Subject has a history of any of the following cardiac conditions within 6 months of screening: myocardial infarction, acute coronary syndrome, unstable angina, new onset atrial fibrillation, new onset atrial flutter, second- or third-degree atrioventricular block, ventricular fibrillation, ventricular tachycardia, heart failure, cardiac surgery, interventional cardiac catheterization (with or without a stent placement), interventional electrophysiology procedure, or presence of implanted defibrillator.

18. Subject has a known active current or history of medically important recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease and Herpes zoster), human immunodeficiency virus (HIV), or any major episode of infection requiring hospitalization or treatment with intravenous (IV) or oral antibiotics within 4 weeks of screening.

19. Subject has a history of congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).

20. Subject has a history of malignancy, except for:

1. Treated (ie, cured) basal cell or squamous cell in situ skin carcinomas

2. Treated (ie, cured) cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years

21. Subject has received investigational drug or device within 1 month of screening.

22. Subject has a history of alcohol, drug, or chemical abuse within the 6 months prior to screening.

23. Subject has a known hypersensitivity to oligonucleotides or any ingredient in the Investigational Product (IP).

24. Subject has prior treatment with GED-0301 or participated in a clinical study involving GED-0301.

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer

Intervention

Drug:
• GED-0301

Locations

Country	Name	City	State
Bulgaria	Multiprofile Hospotal for Active Treatment- Sveti Nikolay Chudotvoretz - LOM EOOD	Lom
Bulgaria	Multiprofile Hospital for Active Treatment Doverie AD	Sofia
Bulgaria	Multiprofile Hospital for Active Treatment Sveti Panteleimon - Sofia AD	Sofia
Canada	London Health Sciences Centre, University Hospital	London	Ontario
Canada	GI Research Institute	Vancouver	British Columbia
Canada	Toronto Digestive Disease Associates Inc	Vaughan	Ontario
Hungary	Pandy Kalman Megyei Korhaz	Siófok
Poland	Centrum Medyczne sw. Lukasza	Czestochowa
Poland	Endoskopia Sp. z o.o.	Sopot
Poland	Centrum Zdrowia Matki, Dziecka i Mlodziezy	Warsaw
Poland	LexMedica Osrodek Badan Klinicznych	Wroclaw
Slovakia	Fakultna nemocnica s poliklinikou F. D. Roosevelta	Banska Bystrica
Slovakia	IBD Centrum s.r.o.	Bratislava
Slovakia	Univerzitna nemocnica Bratislava	Bratislava
Slovakia	KM Management, spol. s r.o.	Nitra
Slovakia	GASTRO I., s.r.o.	Presov
United States	Chevy Chase Clinical Research	Chevy Chase	Maryland
United States	Case Western Reserve University	Cleveland	Ohio
United States	Texas Digestive Disease Consultants - Dallas	Dallas	Texas
United States	Florida Research Network, LLC	Gainesville	Florida
United States	Gastroenterology Center of The Midsouth PC	Germantown	Tennessee
United States	Baylor College of Medicine	Houston	Texas
United States	Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire
United States	University of Kentucky	Lexington	Kentucky
United States	Dean Medical Center	Madison	Wisconsin
United States	University of Miami School of Medicine	Miami	Florida
United States	Gastroenterology Group of Naples	Naples	Florida
United States	Nashville Gastrointestinal Specialists	Nashville	Tennessee
United States	Vanderbilt University	Nashville	Tennessee
United States	Concorde Medical Group	New York	New York
United States	Macks Research Group	Newport Beach	California
United States	McGuire Veterans Affairs Medical Center	Richmond	Virginia
United States	Rochester General Hospital	Rochester	New York
United States	Medical Associates Research Associates	San Diego	California
United States	Texas Digestive Disease Consultants - Southlake	Southlake	Texas
United States	Shafran Gastroenterology Center	Winter Park	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Countries where clinical trial is conducted

United States,  Bulgaria,  Canada,  Hungary,  Poland,  Slovakia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Score (MMS) at Week 8	Clinical remission was defined as a modified Mayo score of = 2, with no individual subscore > 1, at Week 8. The MMS was based on a modification of the total Mayo score (TMS) which included the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the Physician's Global Assessment (PGA) subscore, since this was a global measure that is subjective in nature. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.	Baseline to Week 8
Secondary	Percentage of Participants Who Achieved a Modified Mayo Score of = 2, With Rectal Bleeding Subscore (RBS) of 0 and Stool Frequency Subscore (SFS) and Mayo Endoscopic Subscore = 1 at Week 8	A MMS was used to evaluate disease activity using 3 components: stool frequency, rectal bleeding and endoscopy; the MMS ranges from 0-9 with higher scores indicating greater disease severity.; Stool frequency subscore was defined as 0-3: 0 = Normal number of stools for patient; = 1-2 stools per day more than normal; = 3-4 stools more than normal; = 5 or more stools more than normal; Rectal bleeding (subscore 0-3) was defined as: 0 = No blood seen; = Streaks of blood with stool less than half the time; = Obvious blood with stool most of the time; = Blood alone passes; Endoscopic subscore: Findings were defined as: 0 = Normal or inactive disease; = Mild Disease (erythema, decreased vascular pattern, mild friability); = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions); = Severe Disease (spontaneous bleeding, ulceration)	Baseline to Week 8
Secondary	Percentage of Participants Who Achieved a Mayo Endoscopic Subscore of = 1 at Week 8	A Mayo endoscopic subscore of = 1 was assessed and evaluated in participants who achieved a Mayo endoscopic subscore at Week 8. The endoscopy subscore findings are defined as: 0 = Normal or inactive disease; = Mild Disease (erythema, decreased vascular pattern, mild friability); = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions); = Severe Disease (spontaneous bleeding, ulceration) The endoscopy scores were centrally reviewed. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.	Baseline to Week 8
Secondary	Percentage of Participants Who Achieved a Mayo Endoscopic Subscore of = 1 by Individual Segment at Week 8	A Mayo endoscopic subscore by individual segment (rectum, sigmoid, descending colon, transverse colon, ascending colon/cecum) of = 1 was evaluated at week 8.; The endoscopy subscore findings are defined as: 0 = Normal or inactive disease; = Mild Disease (erythema, decreased vascular pattern, mild friability); = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions); = Severe Disease (spontaneous bleeding, ulceration) The endoscopy scores were centrally reviewed. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.	Baseline to Week 8
Secondary	Percentage of Participants Who Achieved a Clinical Response in the Modified Mayo Score at Week 8	Clinical response in the MMS was defined as a decrease from baseline in the MMS of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS = 1. The MMS was based on the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the PGA subscore. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The RBS was defined as: 0 = No blood seen; = Streaks of blood with stool less than half the time; = Obvious blood with stool most of the time; = Blood alone passes The daily bleeding score represents the most severe bleeding score represents the most severe bleeding of the day.	Baseline to Week 8
Secondary	Percentage of Participants Who Achieved a Mayo Endoscopic Response at Week 8	Endoscopic response was defined as a decrease from baseline of at least 1 point in the Mayo endoscopic subscore. The Mayo endoscopy subscore findings are defined as: 0 = Normal or inactive disease; = Mild Disease (erythema, decreased vascular pattern, mild friability); = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions); = Severe Disease (spontaneous bleeding, ulceration) The endoscopy subscores were centrally reviewed. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.	Baseline and Week 8
Secondary	Percentage of Participants Who Achieved a Clinical Remission in the Total Mayo Score (TMS) at Week 8	Clinical remission in total Mayo score was defined as a total Mayo score of = 2, with no individual subscore >1. The TMS is an instrument designed to measure disease activity of ulcerative colitis. The TMS ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease.; Stool frequency subscore (SFS); Rectal bleeding subscore (RBS); Endoscopic subscore; Physician's Global Assessment (PGA)	Baseline to Week 8
Secondary	Percentage of Participants Who Achieved a Clinical Response in the Total Mayo Score at Week 8	Clinical response in the TMS was defined as a decrease from baseline in the TMS of = 3 points and = 30%, along with a reduction in the RBS of = 1 point or an absolute RBS of = 1 at Week 8. The TMS is an instrument designed to measure disease activity of ulcerative colitis. The TMS ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease.; Stool frequency subscore; Rectal bleeding subscore; Endoscopic subscore; Physician's Global Assessment	Baseline to Week 8
Secondary	The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAE)	A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of mongersen and up to 28 days after the last mongersen dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain.	From the first day of mongersen until 28 days after the last dose of IP or at follow-up visit, whichever occurred earlier; maximum duration of treatment was 56 weeks